Total Payments
$4,652
2024 Payments
$543.63
Companies
44
Transactions
123
Medicare Patients
30,445
Medicare Billing
$9.5M
Payment Breakdown by Category
Food & Beverage$2,405 (51.7%)
Research$1,844 (39.6%)
Education$402.84 (8.7%)
Payments by Nature
| Nature of Payment | Amount | Transactions | Share |
|---|---|---|---|
| Food and Beverage | $2,405 | 96 | 51.7% |
| Unspecified | $1,844 | 3 | 39.6% |
| Education | $402.84 | 24 | 8.7% |
Payments by Type
General
$2,808
120 transactions
Research
$1,844
3 transactions
Top Paying Companies
| Company | Total | Records | Latest Year |
|---|---|---|---|
| Eli Lilly and Company | $1,844 | 3 | $0 (2018) |
| Daiichi Sankyo Inc. | $244.50 | 9 | $0 (2024) |
| E.R. Squibb & Sons, L.L.C. | $225.45 | 7 | $0 (2024) |
| PFIZER INC. | $210.53 | 13 | $0 (2024) |
| Exelixis Inc. | $191.99 | 12 | $0 (2018) |
| Gilead Sciences, Inc. | $174.26 | 4 | $0 (2023) |
| Allergan, Inc. | $166.27 | 7 | $0 (2021) |
| Pharmacyclics LLC, an AbbVie Company | $125.83 | 2 | $0 (2022) |
| Seagen Inc. | $117.01 | 6 | $0 (2023) |
| TESARO, Inc. | $103.15 | 1 | $0 (2017) |
Payment History by Year
| Year | Amount | Transactions | Top Company |
|---|---|---|---|
| 2024 | $543.63 | 28 | Daiichi Sankyo Inc. ($81.43) |
| 2023 | $345.77 | 18 | PFIZER INC. ($79.02) |
| 2022 | $308.28 | 14 | Pharmacyclics LLC, an AbbVie Company ($105.00) |
| 2021 | $380.83 | 16 | Daiichi Sankyo Inc. ($123.73) |
| 2020 | $309.89 | 15 | Allergan, Inc. ($100.46) |
| 2019 | $307.85 | 6 | Gilead Sciences, Inc. ($124.87) |
| 2018 | $1,738 | 9 | Eli Lilly and Company ($1,588) |
| 2017 | $718.40 | 17 | Eli Lilly and Company ($256.66) |
All Payment Transactions
123 individual payment records from CMS Open Payments — Page 2 of 5
| Date | Company | Product | Nature | Form | Amount | Type |
|---|---|---|---|---|---|---|
| 01/24/2024 | Takeda Pharmaceuticals U.S.A., Inc. | VPRIV (Biological) | Food and Beverage | In-kind items and services | $19.46 | General |
| Category: GENETIC DISEASE | ||||||
| 01/18/2024 | Novartis Pharmaceuticals Corporation | KISQALI (Drug) | Food and Beverage | In-kind items and services | $27.04 | General |
| Category: Oncology | ||||||
| 01/06/2024 | PFIZER INC. | IBRANCE (Drug) | Food and Beverage | In-kind items and services | $18.17 | General |
| Category: ONCOLOGY | ||||||
| 12/22/2023 | PFIZER INC. | IBRANCE (Drug) | Education | In-kind items and services | $14.17 | General |
| Category: ONCOLOGY | ||||||
| 12/05/2023 | AVEO Pharmaceuticals, Inc. | FOTIVDA (Drug) | Food and Beverage | In-kind items and services | $17.00 | General |
| Category: Oncology | ||||||
| 11/17/2023 | GlaxoSmithKline, LLC. | OJJAARA (Drug) | Food and Beverage | In-kind items and services | $20.06 | General |
| Category: ONCOLOGY | ||||||
| 11/13/2023 | PFIZER INC. | IBRANCE (Drug) | Education | In-kind items and services | $13.13 | General |
| Category: ONCOLOGY | ||||||
| 11/07/2023 | Daiichi Sankyo Inc. | Enhertu (Drug) | Food and Beverage | In-kind items and services | $27.83 | General |
| Category: ONCOLOGY | ||||||
| 11/03/2023 | Gilead Sciences, Inc. | Trodelvy (Drug) | Food and Beverage | In-kind items and services | $23.65 | General |
| Category: ONC | ||||||
| 10/30/2023 | GENZYME CORPORATION | XENPOZYME (Biological) | Food and Beverage | In-kind items and services | $18.67 | General |
| Category: Genetic Disease | ||||||
| 10/23/2023 | PFIZER INC. | IBRANCE (Drug) | Education | In-kind items and services | $25.00 | General |
| Category: ONCOLOGY | ||||||
| 10/23/2023 | PFIZER INC. | IBRANCE (Drug) | Education | In-kind items and services | $12.80 | General |
| Category: ONCOLOGY | ||||||
| 09/05/2023 | Intuitive Surgical, Inc. | Da Vinci Surgical System (Device) | Food and Beverage | In-kind items and services | $13.25 | General |
| Category: SURGERY | ||||||
| 08/22/2023 | Seagen Inc. | ADCETRIS (Biological) | Food and Beverage | In-kind items and services | $25.53 | General |
| Category: Oncology | ||||||
| 08/04/2023 | ADC Therapeutics America, Inc. | — | Food and Beverage | Cash or cash equivalent | $28.50 | General |
| 06/09/2023 | PharmaEssentia USA Corporation | BESREMI (Drug) | Food and Beverage | In-kind items and services | $22.86 | General |
| Category: Oncology | ||||||
| 05/15/2023 | Takeda Pharmaceuticals U.S.A., Inc. | VPRIV (Biological) | Food and Beverage | In-kind items and services | $20.89 | General |
| Category: GENETIC DISEASE | ||||||
| 05/09/2023 | Merck Sharp & Dohme LLC | KEYTRUDA (Biological) | Food and Beverage | In-kind items and services | $14.01 | General |
| Category: ONCOLOGY | ||||||
| 04/28/2023 | BeiGene USA, Inc. | BRUKINSA (Drug) | Food and Beverage | In-kind items and services | $17.87 | General |
| Category: Oncology | ||||||
| 04/27/2023 | PFIZER INC. | IBRANCE (Drug) | Education | In-kind items and services | $13.92 | General |
| Category: ONCOLOGY | ||||||
| 01/12/2023 | Mirati Therapeutics, Inc. | KRAZATI (Drug) | Food and Beverage | In-kind items and services | $16.63 | General |
| Category: ONCOLOGY | ||||||
| 11/17/2022 | Seagen Inc. | PADCEV (Biological) | Food and Beverage | In-kind items and services | $16.07 | General |
| Category: Oncology | ||||||
| 11/16/2022 | E.R. Squibb & Sons, L.L.C. | OPDIVO (Biological) | Food and Beverage | Cash or cash equivalent | $15.64 | General |
| Category: Oncology | ||||||
| 09/09/2022 | Seagen Inc. | ADCETRIS (Biological) | Food and Beverage | In-kind items and services | $20.35 | General |
| Category: Oncology | ||||||
| 07/28/2022 | PFIZER INC. | IBRANCE (Drug), PAXLOVID | Food and Beverage | In-kind items and services | $16.16 | General |
| Category: ONCOLOGY | ||||||
Research Studies & Clinical Trials
| Study Name | Company | Amount | Records |
|---|---|---|---|
| A PHASE 1B OPEN-LABEL - PHASE 2 RANDOMIZED, DOUBLE-BLINDED STUDY EVALUATING GEMCITABINE AND DOCETAXEL WITH OR WITHOUT OLARATUMAB IN THE TREATMENT OF ADVANCED SOFT TISSUE SARCOMA | Eli Lilly and Company | $1,844 | 3 |
Medicare Billing by Year
| Year | Procedures | Beneficiaries | Services | Submitted | Medicare Paid |
|---|---|---|---|---|---|
| 2023 | 88 | 7,146 | 173,646 | $7.8M | $2.2M |
| 2022 | 90 | 7,037 | 152,975 | $7.5M | $2.1M |
| 2021 | 97 | 8,089 | 172,365 | $8.4M | $2.6M |
| 2020 | 99 | 8,173 | 192,204 | $8.2M | $2.5M |
Total Patients
30,445
Total Services
691,190
Medicare Billing
$9.5M
Procedure Codes
374
All Medicare Procedures & Services
374 procedure records from CMS Medicare Utilization — Page 2 of 15
| HCPCS | Description | Setting | Year | Patients | Services | Charges | Medicare Paid | Ratio |
|---|---|---|---|---|---|---|---|---|
| 85025 | Complete blood cell count (red cells, white blood cell, platelets), automated test and automated differential white blood cell count | Office | 2023 | 419 | 1,259 | $32,734 | $9,516 | 29.1% |
| A9552 | Fluorodeoxyglucose f-18 fdg, diagnostic, per study dose, up to 45 millicuries | Office | 2023 | 56 | 74 | $33,300 | $9,283 | 27.9% |
| 36415 | Insertion of needle into vein for collection of blood sample | Office | 2023 | 383 | 1,008 | $13,029 | $8,435 | 64.7% |
| J9217 | Leuprolide acetate (for depot suspension), 7.5 mg | Office | 2023 | 16 | 58 | $31,900 | $7,928 | 24.9% |
| 83735 | Magnesium level | Office | 2023 | 379 | 1,209 | $27,807 | $7,856 | 28.3% |
| 71260 | Ct scan of chest with contrast | Office | 2023 | 145 | 159 | $79,500 | $7,606 | 9.6% |
| 96417 | Administration of additional new drug or substance into vein, 1 hour or less | Office | 2023 | 104 | 165 | $23,100 | $7,455 | 32.3% |
| 83615 | Lactate dehydrogenase (enzyme) level | Office | 2023 | 379 | 1,209 | $25,389 | $7,106 | 28.0% |
| 96401 | Administration of non-hormonal anti-neoplastic chemotherapy under skin or into muscle | Office | 2023 | 45 | 135 | $22,410 | $6,873 | 30.7% |
| G0498 | Chemotherapy administration, intravenous infusion technique; initiation of infusion in the office/clinic setting using office/clinic pump/supplies, with continuation of the infusion in the community setting (e.g., home, domiciliary, rest home or assisted l | Office | 2023 | 32 | 55 | $55,000 | $6,482 | 11.8% |
| 96365 | Infusion into a vein for therapy, prevention, or diagnosis, 1 hour or less | Office | 2023 | 100 | 127 | $19,685 | $5,665 | 28.8% |
| 99205 | New patient office or other outpatient visit, 60-74 minutes | Office | 2023 | 36 | 36 | $17,640 | $5,592 | 31.7% |
| 84100 | Phosphate level | Office | 2023 | 379 | 1,209 | $19,344 | $5,558 | 28.7% |
| 84550 | Uric acid level, blood | Office | 2023 | 379 | 1,206 | $18,090 | $5,282 | 29.2% |
| J9041 | Injection, bortezomib, 0.1 mg | Office | 2023 | 21 | 1,540 | $178,640 | $4,901 | 2.7% |
| 85055 | Reticulated (young) platelet measurement | Office | 2023 | 58 | 121 | $11,011 | $4,239 | 38.5% |
| 70553 | Mri scan of brain before and after contrast | Office | 2023 | 26 | 28 | $40,768 | $3,929 | 9.6% |
| 96415 | Administration of chemotherapy into vein, each additional hour | Office | 2023 | 87 | 184 | $11,960 | $3,735 | 31.2% |
| J9395 | Injection, fulvestrant, 25 mg | Office | 2023 | 15 | 370 | $86,950 | $3,419 | 3.9% |
| 96372 | Injection of drug or substance under skin or into muscle | Office | 2023 | 202 | 330 | $18,810 | $3,322 | 17.7% |
| Q5110 | Injection, filgrastim-aafi, biosimilar, (nivestym), 1 microgram | Office | 2023 | 12 | 10,980 | $21,960 | $2,888 | 13.1% |
| J9070 | Cyclophosphamide, 100 mg | Office | 2023 | 12 | 172 | $18,060 | $2,532 | 14.0% |
| 82378 | Carcinoembryonic antigen (cea) protein level | Office | 2023 | 72 | 136 | $8,840 | $2,527 | 28.6% |
| 99203 | New patient office or other outpatient visit, 30-44 minutes | Office | 2023 | 30 | 30 | $7,590 | $2,225 | 29.3% |
| J0640 | Injection, leucovorin calcium, per 50 mg | Office | 2023 | 28 | 676 | $10,140 | $2,161 | 21.3% |
About Dr. Mark Olsen, M.D
Dr. Mark Olsen, M.D is a Hematology & Oncology healthcare provider based in Tulsa, Oklahoma. This provider has been registered with the National Plan and Provider Enumeration System (NPPES) since 06/09/2006. The National Provider Identifier (NPI) number assigned to this provider is 1356382592.
According to the Centers for Medicare & Medicaid Services (CMS) Open Payments database, Dr. Mark Olsen, M.D has received a total of $4,652 in payments from pharmaceutical and medical device companies, with $543.63 received in 2024. These payments were reported across 123 transactions from 44 companies. The most common payment nature is "Food and Beverage" ($2,405).
As a Medicare-enrolled provider, Olsen has provided services to 30,445 Medicare beneficiaries, totaling 691,190 services with total Medicare billing of $9.5M. Data is available for 4 years (2020–2023), covering 374 distinct procedure/service records.
Ad
Practice Information
- Specialty Hematology & Oncology
- Location Tulsa, OK
- Active Since 06/09/2006
- Last Updated 05/08/2014
- Taxonomy Code 207RH0003X
- Entity Type Individual
- NPI Number 1356382592
Products in Payments
- OPDIVO (Biological) $208.57
- Cabometyx (Drug) $191.99
- Enhertu (Drug) $151.04
- IBRANCE (Drug) $150.18
- Zydelig (Drug) $124.87
- IMBRUVICA (Drug) $105.00
- VARUBI (Drug) $103.15
- Optune (Device) $101.25
- INJECTAFER (Drug) $93.46
- PADCEV (Biological) $90.02
- XPOVIO (Drug) $82.49
- STRATTICE (Device) $76.31
- ADCETRIS (Biological) $66.16
- ZYTIGA (Drug) $63.99
- LIBTAYO (Biological) $59.80
- INQOVI (Drug) $51.16
- Lenvima (Drug) $45.79
- REBLOZYL (Biological) $41.78
- STRATTICE RECONSTRUCTIVE TISSUE MATRIX BPS (Device) $40.41
- BRUKINSA (Drug) $40.39
Explore
Data Sources
Provider data from NPPES. Payment data from CMS Open Payments. Medicare data from CMS Medicare Provider Utilization. All data is public and updated periodically.
Hematology & Oncology Doctors in Tulsa
Dr. Edwin Mccreary, M.d, M.D
Hematology & Oncology — Payments: $477,532
Hematology & Oncology $477,532
Dr. Ali Moussa, M.d, M.D
Hematology & Oncology — Payments: $11,003
Hematology & Oncology $11,003
Supriya Koya, Md, MD
Hematology & Oncology — Payments: $6,558
Hematology & Oncology $6,558
Dr. Vicki Baker, M.d, M.D
Hematology & Oncology — Payments: $5,946
Hematology & Oncology $5,946
Dr. Jennifer Trottman, Md, MD
Hematology & Oncology — Payments: $4,488
Hematology & Oncology $4,488
Dr. Kevin Weibel, D.o, D.O
Hematology & Oncology — Payments: $4,174
Hematology & Oncology $4,174